LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Insight into a patient’s risk for hereditary cancer

VistaSeq

Approximately five to ten percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.1

  • Genetic mutations have been associated with more than 50 hereditary cancer syndromes.1
  • Patients with genetic mutations associated with a hereditary cancer syndrome are at a higher risk of developing certain types of cancer than the general population, and usually at earlier age of onset than is typical.
  • Genetic testing can help determine whether a patient with a suspected personal or family history of cancer has an inherited gene mutation.
  • Genetic testing can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome.

VistaSeq® hereditary cancer panels are multi-gene tests that detect inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.

VistaSeq Hereditary Cancer panelprovides an assessment of inherited genetic mutations known to be associated with hereditary cancer syndromes. Genes tested in this panel include APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.

VistaSeq Hereditary Cancer panel without BRCAintended for individuals who have already had a BRCA1 and BRCA2 gene assessment, but for whom results of that testing were negative and personal or family history warrant assessment of additional genes. Genes tested in this panel include APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.

VistaSeq Brain/CNS/PNS Cancer panelGenes tested in this panel include ALK, APC, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PTCH1, RB1, SMARCB1, SUFU, TP53, and VHL.

VistaSeq Breast and GYN Cancer panelGenes tested in this panel include ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2,EPCAM, FAM175A, FANCC, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53.

VistaSeq Breast Cancer panel: Genes tested in panel include ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, FAM175A, MRE11A, MUTYH, NF1, NBN, PALB, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53.

VistaSeq Colorectal Cancer panel: Genes tested in this panel include APC, ATM, AXIN2, BLM, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11 and TP53.

VistaSeq Endocrine Cancer panel: Genes tested in this panel include CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53 and VHL.

VistaSeq GYN Cancer panelGenes tested in this panel include BRCA1, BRCA2, CHEK2, EPCAM, MHL1, MSH2, MSH6, MUTYH, PMS2, PTEN and TP53.

VistaSeq High Risk Colorectal Cancer panelGenes tested in this panel include APC, EPCAM, MLH1, MSH2, MSH6, MUTYH and PMS2.

VistaSeq High/Moderate Risk Breast Cancer panelGenes tested in tested in this panel include ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11 and TP53.

VistaSeq Pancreatic Cancer panelGenes tested in this panel include APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 and VHL.

VistaSeq Renal Cell Cancer panel: Genes tested in this panel include EPCAM, FH, FLCN, GPC3, MET, MITF (c.952G>A), MLH1, MSH2, MSH6, PTEN, PMS2, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL and WT1.

Additional hereditary cancer testing options

BRCAssure: Patients with BRCA mutations are at increased risk for breast, ovarian, and other cancers. Knowing your patient’s BRCA mutation status may assist in development of tailored prevention and treatment strategies. For this reason, Integrated Genetics offers a suite of BRCAssure tests to meet patients’ varied needs. 

Mutation-specific sequencing: For family testing when a mutation has been specifically identified through one of our VistaSeq panels.

Other testing options

In addition to hereditary cancer screening, we also offer: serum screening and noninvasive prenatal testing (NIPT, sometimes called NIPS or cell-free DNA), including the pioneering whole-genome NIPTcarrier screening, from comprehensive to single-gene; and diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples.

Ask questions about genetic testing options or results, or schedule an appointment.

About results logo

About your results

If you have already had a test performed, we can help answer questions about results.

Reference

  1. Genetic Testing for Hereditary Cancer Syndromes. National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-t.... Accessed September 15, 2017.